Related by context. All words. (Click for frequent words.) 69 postoperative mortality 67 recurrent VTE 66 thrombotic complications 65 bowel resection 65 rebleeding 65 postoperative AF 65 recurrent venous thromboembolism 65 thromboembolic 65 symptomatic intracranial hemorrhage 65 Postoperative complications 65 angiographic restenosis 65 cerebral vasospasm 65 postoperative pulmonary 65 colorectal adenoma 64 variceal bleeding 64 corticosteroid dose 64 postoperative complication 64 vaginal hysterectomy 64 R0 resection 64 upper gastrointestinal bleeding 64 glycated hemoglobin levels 64 CRBSI 64 H. pylori eradication 63 salivary flow 63 endometrial carcinoma 63 polyp recurrence 63 postoperative atrial fibrillation 63 post surgical adhesions 63 bilateral oophorectomy 63 PSADT 63 venous blood clots 63 adenoma recurrence 63 COPD exacerbations 63 debulking surgery 63 thromboembolic events 63 myocardial reperfusion 63 PASI scores 63 nonvertebral fractures 63 postoperative bleeding 63 advanced adenoma 63 postoperative morbidity 63 Febrile neutropenia 63 postoperative infection 63 biochemical relapse 63 secondary efficacy endpoint 63 inhospital 63 PSA nadir 63 serum urate levels 63 arterial thromboembolic events 63 venous thromboembolic events 63 renal scarring 63 reinfarction 62 Erythropoietic therapies may 62 nonvertebral fracture 62 lumbar disk herniation 62 atheroma volume 62 MS relapses 62 precancerous cervical 62 genital herpes infections 62 recurrent myocardial infarction 62 Contrast Induced Nephropathy CIN 62 metachronous 62 intraoperative complications 62 hemorrhagic complications 62 gout flares 62 serum aminotransferase levels 62 atrophic gastritis 62 serum uric acid 62 recurrent UTI 62 delayed CINV 62 Chronic pancreatitis 62 annualized relapse 62 contrast induced nephropathy 62 femoral neck fracture 62 postoperative infections 62 platelet reactivity 62 sustained virologic response 61 morphometric vertebral fractures 61 locoregional recurrence 61 variceal 61 % CI #.#-#.# [008] 61 serum sodium levels 61 postoperative hemorrhage 61 neutrophil count 61 hypophosphatemia 61 perioperative morbidity 61 androgen suppression 61 Radical prostatectomy 61 malignant neoplasm 61 CP CPPS 61 dysmenorrhoea 61 symptomatic VTE 61 anastomotic leak 61 perioperative complications 61 hypoperfusion 61 severe rotavirus gastroenteritis 61 eosinophilia 61 perioperative mortality 61 postoperative delirium 61 antithrombotic therapy 61 HBeAg seroconversion 61 pCR 61 COPD exacerbation 61 CMV disease 61 spontaneous preterm birth 61 Clostridium difficile infections 61 microbiological eradication 61 external genital lesions 61 invasive ductal 61 systemic toxicity 61 hematological toxicity 61 venous thromboembolic disease 61 total thyroidectomy 61 overt hepatic encephalopathy HE 61 EXJADE 61 renal toxicity 61 IV bisphosphonates 60 chronic rhinosinusitis 60 CMV infection 60 Heavy menstrual bleeding 60 nonmelanoma skin cancers 60 OAB symptoms 60 hyperphenylalaninemia HPA due 60 invasive candidiasis 60 chlamydial infection 60 binary restenosis 60 parathyroidectomy 60 autoantibody levels 60 severe asthma exacerbations 60 nocturnal hypoglycemia 60 parasitemia 60 candidemia 60 concomitant antibiotics 60 octreotide LAR 60 serum PTH 60 hepatorenal syndrome 60 liver metastasis 60 glomerular filtration 60 wound dehiscence 60 aneurysm rupture 60 complete cytogenetic response 60 CR nPR 60 radical prostatectomy RP 60 pretest probability 60 nephrotoxicity 60 Vancocin p = 60 plasma cortisol 60 dysplastic lesions 60 SRBD 60 severe exacerbations 60 neovascularisation 60 postoperative nausea 60 CIN3 60 vasospasm 60 vertebral fracture 60 radicular pain 60 Pulmonary Embolism PE 60 plasma HCV RNA 60 TNF antagonist 60 diabetic gastroparesis 60 PONV 60 operable breast cancer 60 TURBT 60 CCyR 60 invasive aspergillosis 60 pelvic lymphadenectomy 60 atherothrombotic events 60 curative resection 60 infarct size 60 prostate cancer CaP 60 elevated ALT 60 knee osteoarthritis OA 60 intraoperative bleeding 60 pathologic fractures 60 antiplatelet medication 60 intracranial hemorrhage ICH 60 serum urate 60 inflammatory lesions 60 biochemical recurrence 60 histologic subtype 60 cranial irradiation 60 UPPP 59 β blockers 59 precursor lesions 59 C. difficile colitis 59 chorioamnionitis 59 intravascular hemolysis 59 primary hyperparathyroidism 59 PRADAXA #mg 59 virological response 59 serum phosphate 59 Tumor shrinkage 59 renal flares 59 IOP lowering 59 p = #.# [003] 59 haematological toxicity 59 undergoing radical prostatectomy 59 subtrochanteric 59 hippocampal atrophy 59 HeFH 59 endometrial hyperplasia 59 MACCE 59 postoperative complications 59 adrenalectomy 59 ertapenem 59 nocturnal hypoglycaemia 59 GI bleeds 59 deep venous thromboses 59 femoral shaft fracture 59 androgen ablation 59 refractory ischemia 59 Lupuzor ™ 59 HER2 expression 59 microvascular complications 59 ipsilateral stroke 59 chronic periodontitis 59 related hematological toxicity 59 metastatic carcinoid tumors 59 artery stenosis 59 anterior uveitis 59 recurrent atrial fibrillation 59 serum ALT 59 VUR 59 CRBSIs 59 A1c levels 59 oral anticoagulant therapy 59 clodronate 59 Hypotension 59 amyloid deposition 59 CIN2 + 59 prostate adenocarcinoma 59 polyp detection 59 cardiovascular hospitalization 59 neutrophil counts 59 thromboembolic disease 59 osteoporotic fractures 59 CAUTI 59 S. aureus infection 59 systolic dysfunction 59 alanine aminotransferase ALT 59 urinary N telopeptide 59 intravesical therapy 59 pulmonary exacerbation 59 abnormal uterine bleeding 59 serum HBV DNA 59 intracerebral haemorrhage 59 incontinence episodes 59 liver resection 59 HIV HCV coinfected 59 serum calcium levels 59 renal biopsy 59 capillary leakage 59 tumor resection 59 genital ulcers 59 premenstrual syndrome PMS 59 thromboembolic complications 59 eosinophil count 59 endophthalmitis 59 coronary stenosis 59 viral titers 59 colonoscopic 59 hematologic abnormalities 59 neointimal hyperplasia 59 Surgical excision 59 carotid stenosis 59 atrioventricular block 59 dosing frequency 59 CI #.#-#.# [001] 59 leiomyomas 59 malarial anemia 59 FluCAM arm 59 thromboembolism 59 serum LDL cholesterol 59 gallstone formation 59 hyperprolactinemia 59 colectomy 58 gastric cardia 58 colorectal adenomas 58 vesicoureteral reflux 58 gastrointestinal bleeds 58 hypoglycaemic episodes 58 TEAEs 58 hypertrophic scars 58 haematologic 58 acute GvHD 58 serum testosterone 58 alanine aminotransferase 58 cilostazol 58 lymphocytosis 58 T2 lesions 58 abnormal Pap smears 58 moderately emetogenic 58 de ath 58 detectable HCV RNA 58 % CI #.#-#.# [007] 58 KRAS mutations occur 58 histological subtype 58 digestive tract cancers 58 tumor recurrence 58 foveal thickness 58 pulmonary resection 58 vestibular dysfunction 58 Ileus 58 NNT = 58 fetal malformations 58 aminotransferase levels 58 specific antigen PSA 58 leukocyte count 58 pancreatectomy 58 virological failure 58 serum phosphate levels 58 intracerebral hemorrhage 58 reinterventions 58 CVD mortality 58 tissue oxygenation 58 lowering blood glucose 58 LAGB 58 hepatectomy 58 hematologic toxicity 58 arterial calcification 58 coronary artery occlusion 58 leucopenia 58 colorectal carcinoma 58 symptomatic intracranial 58 underwent resection 58 mm ³ 58 recurrent miscarriage 58 imipenem 58 tamponade 58 ischemic complications 58 Liver transplantation 58 bacteriuria 58 keloid scarring 58 intravenous bisphosphonates 58 colorectal polyp 58 recurrent ischemic stroke 58 fragility fracture 58 thoracoscopic lobectomy 58 ALND 58 ruptured aneurysms 58 relapsed MM 58 Parathyroid hormone 58 nonfatal MI 58 anovulatory infertility 58 plasma uric acid 58 macrovascular events 58 radioiodine therapy 58 definite stent thrombosis 58 T2DM 58 meniscectomy 58 platelet activation 58 acetabular dysplasia 58 thrombotic events 58 lymphadenectomy 58 parasitaemia 58 serum PSA 58 venous thromboembolic 58 overt hepatic encephalopathy 58 SCr 58 HAM D# scores 58 elevated IOP 58 posaconazole 58 urolithiasis 58 osteosarcomas 58 gastric acidity 58 calculated creatinine clearance 58 ALT elevation 58 stent implantation 58 #.#/#.# mmHg [001] 58 arterial stiffening 58 5-fluorouracil/leucovorin 58 paraprotein 58 hip BMD 58 creatine kinase MB 58 cervical intraepithelial neoplasia 58 AA Amyloidosis 58 plasma creatinine 58 Hip fracture 58 fibrin deposition 58 neurocognitive deficits 58 prednisone prednisolone 58 HGPIN 58 mediastinal 58 amenorrhoea 58 malignant neoplasms 58 ventricular tachyarrhythmia 58 cirrhotic patients 58 cecal intubation 58 recurrent DVT 58 pulmonary metastases 58 serum creatinine levels 58 intrathoracic 58 atherothrombotic 58 HbA1C levels 58 sUA levels 58 Ishak fibrosis score 58 serum cortisol 58 atherogenic dyslipidemia 58 blood phenylalanine Phe 58 elevated transaminases 58 HbA 1c levels 58 renal cell carcinomas 58 androgen deprivation 58 antimicrobial prophylaxis 58 EBRT 58 severe neutropenia 58 fibrosis scarring 58 artery thickening 58 oral FTY# 58 invasive ductal breast cancer 58 carotid IMT 58 Venous thromboembolism 58 hepatocellular carcinoma liver 58 transfusion transmitted 58 transaminase levels 58 dysfunctional voiding 58 patients undergoing CABG 58 node metastases 58 gastro esophageal reflux 58 renal cysts 58 asthma exacerbations 58 T1c 58 baseline LDH 58 parathyroid carcinoma 58 ventricular remodeling 58 NMIBC 58 Toxicities 58 distal colon cancer 58 morbidity mortality 57 serum calcium 57 luminal diameter 57 EDSS scores 57 lymphocyte counts 57 gastro oesophageal reflux 57 pT3 57 hepatic cirrhosis 57 fluoroquinolone resistance 57 baseline HbA1c 57 sustained virological response 57 adjunctive placebo 57 LHRH agonists 57 hemodilution 57 SUVmax 57 PRADAXA 57 cortisol secretion 57 angiographic outcomes 57 elective PCI 57 HBV infections 57 CHD CVD 57 blood glucose concentrations 57 ibandronate 57 recurrent ischemia 57 urinary excretion 57 response CCyR 57 embolic stroke 57 graft occlusion 57 corticosteroid therapy 57 serum HCV RNA 57 recurrent genital herpes 57 erythema nodosum 57 GERD symptoms 57 NIHSS score 57 prolonged QT interval 57 obstructive CAD 57 cytologic 57 % CI #.#-#.# [003] 57 axillary node 57 nonadherence 57 gastrointestinal toxicity 57 Severe hypoglycemia 57 cytoreduction 57 hypoglycemic episodes 57 acute GVHD 57 ADHF 57 chronic thromboembolic pulmonary 57 Aloxi injection 57 postpartum haemorrhage 57 metastatic lesions 57 lactate dehydrogenase 57 hematologic parameters 57 Infusion Reactions Severe 57 gastric adenocarcinoma 57 serum clusterin levels 57 ximelagatran 57 grade cervical intraepithelial 57 Cimzia TM 57 interferon ribavirin 57 venous thrombosis 57 intravitreal injections 57 advanced adenomas 57 perioperatively 57 thromboembolic diseases 57 Cesarean deliveries 57 LNG IUS 57 intermittent hypoxia 57 cervicitis 57 adenoma 57 plasma triglycerides 57 extracapsular extension 57 EUS FNA 57 postprocedure 57 PAOD 57 hyperammonemia 57 thromboprophylaxis 57 left ventricular diastolic 57 intestinal metaplasia 57 serum homocysteine 57 sUA 57 bacterial prostatitis 57 Helicobacter pylori infection 57 neurodevelopmental impairment 57 reoperations 57 adnexal mass 57 HBV DNA levels 57 complete cytogenetic 57 DAS# remission 57 lung metastasis 57 transfusion syndrome 57 cytogenetic response 57 Tranexamic acid 57 cystectomy 57 XIENCE V demonstrated 57 Natalizumab 57 mucosal inflammation 57 nonalcoholic steatohepatitis NASH 57 oncologic outcomes 57 cytomegalovirus infection 57 postdischarge 57 ICD shocks 57 neurologic sequelae 57 cardiovascular hospitalizations 57 VT VF 57 cytopenia 57 preterm neonates 57 polypoid 57 cholecystitis 57 skeletal metastases 57 Kepivance 57 oxycodone CR 57 Combination therapy 57 CHD mortality 57 albumin excretion rate 57 hypercalcaemia 57 QTcF 57 intact parathyroid hormone 57 intestinal polyps 57 postoperative ileus 57 haematuria 57 tracer uptake 57 aspartate aminotransferase 57 pyelonephritis 57 liver histology 57 atypical fractures 57 serum testosterone levels 57 neutropenic patients 57 systemic corticosteroid 57 varicella infection 57 recurrent glioblastoma multiforme 57 reperfusion injury 57 GI toxicity 57 hypoxemia 57 proliferative diabetic retinopathy 57 Aortic stenosis 57 latent celiac disease 57 lymphatic cancers 57 ICD implantation 57 fatal IHD 57 treat dysmenorrhea 57 radiotherapy RT 57 Prostatitis 57 distensibility 57 mL/min/#.# m 2 57 CR CRu 57 tapentadol ER 57 testicular tumors 57 antibiotic prophylaxis 57 pathologic fracture 57 coagulation abnormalities 57 hepatic enzymes 57 swelling edema 57 vasodilatation 57 asthma exacerbation 57 SLNB 57 salmeterol HFA MDI 57 tirofiban 57 Target Lesion Revascularization TLR 57 μg liter 57 pulmonary exacerbations 57 Exacerbation 57 malperfusion 57 myocardial infarct size 57 undetectable PSA 57 STRIDE PD 57 acromegalic patients 57 RYGB 57 neurodevelopmental outcomes 57 AGHD 57 aminotransferase ALT 57 atrial arrhythmias 57 precancerous cervical lesions 57 myeloperoxidase 56 cancerous colon polyps 56 preoperative PSA 56 symptomatic atrial fibrillation 56 hypercalcemia 56 #.#ng/ml 56 proton MR spectroscopy 56 S. aureus colonization 56 spontaneous bacterial peritonitis 56 SGPT 56 H. pylori infection 56 neurologic deficits 56 colon resection 56 restenosis reblockage 56 extubation 56 colorectal cancer incidence 56 revascularisation 56 severe oral mucositis 56 RSV hospitalizations 56 bicuspid aortic valves 56 spinal metastases 56 ischemic mitral regurgitation 56 catheter angiography 56 DHEA supplementation 56 neurocognitive outcomes 56 varices 56 ductal carcinomas 56 antiangiogenic therapy 56 periprocedural 56 recanalization 56 ruboxistaurin 56 thyrotropin 56 distant metastasis 56 protein excretion 56 paroxysmal AF 56 rehospitalization 56 hemorrhagic cystitis 56 mixed hyperlipidemia 56 lichen planus 56 invasive fungal infection 56 Pulmonary embolism 56 acute aortic dissection 56 vaso occlusive crisis 56 urinary tract symptoms LUTS 56 intensive statin therapy 56 nighttime awakenings 56 hyperbilirubinemia 56 thrombus formation 56 oral diclofenac 56 antireflux surgery 56 spontaneous preterm delivery 56 pyridostigmine 56 neurologic dysfunction 56 opioid analgesia 56 mg kg dose 56 % Confidence Interval 56 elevated uric acid 56 aminotransferases 56 pH#N# 56 serum concentrations 56 radical nephrectomy 56 Carotid endarterectomy 56 HER2 overexpression 56 serum sodium 56 haemorrhagic stroke 56 HBeAg positive patients 56 Catheter Associated 56 neoplastic lesions 56 axillary dissection 56 non valvular atrial 56 albumin excretion 56 hepatic fibrosis 56 PLX STROKE targeting 56 ileus 56 postoperative inflammation 56 morphological abnormalities 56 chronic idiopathic thrombocytopenic purpura 56 CIMZIA ™ 56 rFVIIa 56 homocysteine concentrations 56 mmHg diastolic 56 Crohn Disease Activity 56 revascularization procedure 56 hemoptysis 56 timepoints 56 cardiovascular morbidity 56 nadroparin 56 response pCR 56 Kaplan Meier estimates 56 de aths 56 recurrent UTIs 56 hyperplastic polyps 56 neutropenic fever 56 Arch Intern Med 56 neutropenic 56 lobular cancer 56 platelet inhibition 56 hyperalgesia 56 neointimal 56 thyroid carcinoma 56 NATRECOR ® 56 recurrences 56 EGFRIs 56 coinfection 56 ziconotide 56 Subarachnoid hemorrhage 56 type 1diabetes 56 neurologic complications 56 p = .# [002] 56 sacral neuromodulation 56 delayed onset CINV 56 preterm deliveries 56 clinically meaningful reductions 56 male hormones androgens 56 HbF 56 posttreatment 56 cardioembolic stroke 56 LVNC 56 teriflunomide 56 immuno suppression 56 conjunctival hyperemia 56 antibody titer 56 dysglycemia 56 pericardial effusion 56 glycosylated hemoglobin HbA1c 56 ischemic cardiomyopathy 56 aminotransferase 56 Oral mucositis 56 eculizumab therapy 56 pretreatment serum 56 pneumonectomy 56 periprocedural MI 56 unstable angina pectoris 56 anemia hemoglobin 56 endotoxemia 56 bone metastasis 56 gastrointestinal GI bleeding 56 nonalcoholic steatohepatitis 56 hematopoietic cancers 56 perinatal transmission 56 sternal wound infection 56 Antibiotic prophylaxis 56 tumor regressions 56 ADPKD 56 serum bicarbonate 56 esophageal cancers 56 bisphosphonate therapy 56 incidence ≥ 56 intima media thickness 56 allograft rejection 56 thrombo embolic 56 oocytes retrieved 56 parkinsonian symptoms 56 CDAI score 56 chronic rhinosinusitis CRS 56 urothelial carcinoma 56 salmeterol fluticasone 56 segment binary restenosis 56 hepatic enzyme 56 metastatic malignant 56 receiving XGEVA 56 ispinesib administered 56 hyperhomocysteinemia 56 vidofludimus 56 MCyR 56 Thrombocytopenia 56 allogeneic HSCT 56 timepoint 56 lymphocyte count 56 Adenomas 56 gastrointestinal toxicities 56 PNH patients 56 hyperkalemia 56 XIENCE V PROMUS Stent 56 mutated K ras 56 mycophenolate mofetil MMF 56 MRSA colonization 56 orchiectomy 56 PSVT 56 breast cancer recurrences 56 atopic disease 56 lymph node dissection 56 Thal Dex 56 thyrotropin levels 56 statistical significance p 56 knee arthroscopy 56 fetal chromosomal 56 bioavailable testosterone 56 urinary albumin excretion 56 myopathy rhabdomyolysis 56 variceal hemorrhage 56 unruptured aneurysm 56 PEGylated interferon beta 1a 56 nodal metastases 56 virologic failure 56 GISTs 56 neonatal morbidity 56 ARCOXIA 56 serum estradiol 56 iPTH 56 atherosclerotic progression 56 PHPT 56 hyperoxaluria 56 radiochemotherapy 56 esophageal carcinoma 56 Mucositis 56 thiazide diuretic 56 cardiac dysfunction 56 Serious adverse reactions 56 gastrointestinal hemorrhage 56 mmHg p = 56 stent thromboses 56 TMP SMX 56 adenomatous 56 CMV reactivation 56 onset diabetes mellitus 56 esophagogastroduodenoscopy 56 DES implantation 56 HNSCC 56 Complication rates 56 cerebrovascular events 56 ductal cancer 56 S. aureus infections 56 gastrointestinal perforation 56 total abdominal hysterectomy 56 cytoreductive surgery 56 postop 56 carcinoids 56 mg/m2 dose 56 adenomatous polyps 56 cardiac biomarkers 56 Calcium intake 56 eradicate H. pylori 56 secondary hyperparathyroidism 56 gallstone disease 56 intravenous diuretics 56 virologic breakthrough 56 Severe hypersensitivity reactions 56 interstitial brachytherapy 56 bile duct cancers 56 thrombocytosis 56 ASCUS 56 obstructive coronary artery 56 medication nonadherence 56 DVT PE 56 posttransplant 56 fluid overload 56 strong CYP#A# inducers 56 Fibrillex TM 56 Myocardial infarction 56 cerebral infarction 56 Scheuermann kyphosis 56 T2 lesion volume 56 oral anticoagulation 56 percutaneous interventions 55 arteriography 55 metastatic neuroendocrine tumors 55 perinatal complications 55 NSAID therapy 55 vomiting PONV 55 steroid dexamethasone 55 undetectable viral 55 microvascular dysfunction 55 myocardial ischaemia 55 PIGF 55 Folate deficiency 55 nosocomial infection 55 TAXUS p value 55 Thalomid ® 55 diskectomy 55 Hematologic toxicity 55 HBeAg 55 Operative mortality 55 revascularization procedures 55 reintervention 55 ventricular dysfunction 55 Clinically significant 55 EDARBI 55 genitourinary tract 55 nonoperative treatment 55 #mg dose [002] 55 CIMZIA TM 55 colon adenomas 55 overt nephropathy 55 p = NS 55 flutamide 55 cerebral oxygen saturation 55 epidural steroid injections 55 ventricular enlargement 55 Uncontrolled hypertension 55 mIU ml 55 peri procedural 55 serum parathyroid hormone 55 hyperglycaemia 55 pathological fractures 55 tardive dyskinesia TD 55 Adjuvant chemotherapy 55 postoperative radiotherapy 55 benign nodules 55 postsurgical pain 55 potentially cancerous polyps 55 urate levels 55 blood Phe levels 55 urethral strictures 55 RLS symptoms 55 virologic response 55 oropharyngeal 55 H. pylori infections 55 gastrointestinal adverse reactions 55 reblockage 55 empiric treatment 55 serum lipid levels 55 Nocturia 55 induce remission 55 N telopeptide 55 serum phosphorus levels 55 metastatic bone 55 clostridium difficile infection 55 psoriatic arthritis PsA 55 cardiac repolarization 55 microbiologically evaluable 55 post thrombotic syndrome 55 serum potassium 55 forodesine 55 paroxysmal atrial fibrillation 55 RBP4 levels 55 vulvovaginal candidiasis 55 erythrocyte sedimentation rate 55 rimonabant #mg 55 noncardiac surgery 55 choroidal neovascularization CNV 55 AST ALT 55 serum potassium levels 55 fragility fractures 55 dosing cohort 55 Diabetic nephropathy 55 plasma glucose levels 55 lymph node metastasis 55 cytogenic 55 epithelial ovarian 55 cartilage degeneration 55 systemic embolism 55 chemoradiotherapy 55 asymptomatic carotid stenosis 55 antigen PSA levels 55 noncardiovascular mortality 55 imatinib therapy 55 inotropic 55 plasminogen activators 55 coadministration 55 pulmonary dysfunction 55 creatinine ratio 55 dose cohort 55 liver decompensation 55 XL# administered orally 55 anal cancers 55 untreated celiac disease 55 repolarization 55 pneumococcal infection 55 carotid revascularization 55 monoclonal gammopathy 55 glucocorticoid therapy 55 lumbar spinal stenosis 55 heavy menstrual bleeding 55 angiographically 55 lipid lowering therapy 55 Stomach stapling 55 myelodysplastic myeloproliferative diseases 55 corticosterone levels 55 HPA axis suppression 55 BARACLUDE resistance 55 menstrual bleeding 55 pheochromocytoma 55 contralateral breast cancer 55 neoplasias 55 related bloodstream infections 55 femoral neck fractures 55 mesilate 55 esophagitis 55 seropositivity 55 tumoral 55 Generalized anxiety disorder 55 beta blocker therapy 55 unresectable tumors 55 mediastinitis 55 capillary permeability 55 electrical cardioversion 55 MULTAQ 55 APTIVUS r 55 preintervention 55 anagrelide 55 ALT elevations 55 neurologic impairment 55 intimal hyperplasia 55 torsade de pointes 55 noncardiac 55 febrile neutropenia 55 revascularizations 55 clinically localized prostate